These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treatment Outcomes of Stereotactic Ablative Body Radiotherapy on Extra-cranial Oligometastatic and Oligoprogressive Breast Cancer: Mature Results from a Single Institution Experience. Armstrong S; Makris A; Belessiotis-Richards K; Abdul-Latif M; Ostler P; Shah N; Miles D; Tsang YM Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):362-369. PubMed ID: 38575431 [TBL] [Abstract][Full Text] [Related]
5. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study. Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737 [TBL] [Abstract][Full Text] [Related]
6. Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease. He K; Hong DS; Tang C; Sezen D; Cox L; Maleki A; Bertolet G; Nguyen QN; Comeaux NI; Schuda L; Chen D; Welsh JW Radiother Oncol; 2023 Jun; 183():109618. PubMed ID: 36921766 [TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of stereotactic ablative radiotherapy (SABR) for metastatic lung lesions (MLLs) in comparison with a contemporaneous cohort of primary lung lesions (PLLs). Oskan F; Dzierma Y; Wagenpfeil S; Rübe C; Fleckenstein J J Thorac Dis; 2017 Mar; 9(3):742-756. PubMed ID: 28449482 [TBL] [Abstract][Full Text] [Related]
8. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases. Filippi AR; Badellino S; Guarneri A; Levis M; Botticella A; Mantovani C; Ragona R; Racca P; Buffoni L; Novello S; Ricardi U Technol Cancer Res Treat; 2014 Feb; 13(1):37-45. PubMed ID: 23819496 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression. Ho CB; Tsai JT; Chen CY; Shiah HS; Chen HY; Ting LL; Kuo CC; Lai IC; Lai HY; Chung CL; Lee KL; Tzeng HE; Lee KH; Lee HL; Chen SW; Chiou JF Diagnostics (Basel); 2023 Apr; 13(9):. PubMed ID: 37174988 [TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in medically inoperable early stage lung cancer patients treated with stereotactic ablative radiation therapy (SABR): Turkish Radiation Oncology Society Multicentric Study. Sahin B; Atalar B; Kaytan Saglam E; Akgun Z; Abacioglu U; Arifoglu A; Ozyar E; Yaprak G; Ozseker Isik N; Guney Y; Caglar HB; Karaman S; Igdem S; Selek U; Berber T; Oner Dincbas F; Sengoz M; Yucel S; Demiral AN; Akyurek S Clin Respir J; 2020 Nov; 14(11):1050-1059. PubMed ID: 32749053 [TBL] [Abstract][Full Text] [Related]
11. Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients. Ma MW; Li HZ; Gao XS; Liu MZ; Yin H; Yang KW; Chen JY; Ren XY; Wang D Curr Oncol; 2022 Oct; 29(10):7832-7841. PubMed ID: 36290896 [TBL] [Abstract][Full Text] [Related]
12. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma. McDermott RL; Mihai A; Dunne M; Keys M; O'Sullivan S; Thirion P; ElBeltagi N; Armstrong JG Clin Oncol (R Coll Radiol); 2021 May; 33(5):292-299. PubMed ID: 33309479 [TBL] [Abstract][Full Text] [Related]
13. A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). Radwan N; Phillips R; Ross A; Rowe SP; Gorin MA; Antonarakis ES; Deville C; Greco S; Denmeade S; Paller C; Song DY; Diehn M; Wang H; Carducci M; Pienta KJ; Pomper MG; DeWeese TL; Dicker A; Eisenberger M; Tran PT BMC Cancer; 2017 Jun; 17(1):453. PubMed ID: 28662647 [TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases. Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057 [TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292 [TBL] [Abstract][Full Text] [Related]
16. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760 [TBL] [Abstract][Full Text] [Related]
17. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159 [TBL] [Abstract][Full Text] [Related]
18. Improved local control following dose-escalated stereotactic ablative radiation therapy (SABR) for metastatic sarcomas: An international multi-institutional experience. Singh R; Konrad A; Roubil JG; Jenkins J; Davis J; Austin Vargo J; Gogineni E; Sharma S Radiother Oncol; 2024 Jan; 190():110020. PubMed ID: 38007042 [TBL] [Abstract][Full Text] [Related]